Potential biologic markers in Burkitt's lymphoma

T. P. Waalkes, C. W. Gehrke, W. A. Bleyer, R. W. Zumwalt, C. L. Olweny, K. C. Kuo, D. B. Lakings, S. A. Jacobs

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Specific biochemical molecules used as potential biologic markers, including modified nucleosides, polyamines, and pyrimidine catabolic end products, were quantitatively measured in the urine of seven patients with Burkitt's lymphoma before, during, and after one or more courses of therapy. The results of this preliminary study demonstrated that patients with this disease frequently excrete significantly increased amounts of modified nucleosides (considered to be derived primarily from transfer ribonucleic acid), polyamines, and β aminoisobutyric acid during the course of their disease. With successful treatment and rapid destruction of tumor cells, a concomitant rise in these molecules occurs. Elevations were observed prior to chemotherapy and changes in levels associated with treatment or tumor progression appeared to correlate with disease status and to aid in assessing antitumor response. Periodic follow up analysis of these molecules may be helpful in appraising relapse or recurrence of the malignancy prior to overt evidence of tumor by existing clinical means.

Original languageEnglish (US)
Title of host publicationCANCER CHEMOTHER.REP.
Pages721-727
Number of pages7
Volume59
Edition4
StatePublished - 1975
Externally publishedYes

Fingerprint

Burkitt Lymphoma
Biomarkers
Polyamines
Neoplasms
Pyrimidine Nucleosides
Aminoisobutyric Acids
Recurrence
Transfer RNA
Nucleosides
Therapeutics
Urine
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Waalkes, T. P., Gehrke, C. W., Bleyer, W. A., Zumwalt, R. W., Olweny, C. L., Kuo, K. C., ... Jacobs, S. A. (1975). Potential biologic markers in Burkitt's lymphoma. In CANCER CHEMOTHER.REP. (4 ed., Vol. 59, pp. 721-727)

Potential biologic markers in Burkitt's lymphoma. / Waalkes, T. P.; Gehrke, C. W.; Bleyer, W. A.; Zumwalt, R. W.; Olweny, C. L.; Kuo, K. C.; Lakings, D. B.; Jacobs, S. A.

CANCER CHEMOTHER.REP.. Vol. 59 4. ed. 1975. p. 721-727.

Research output: Chapter in Book/Report/Conference proceedingChapter

Waalkes, TP, Gehrke, CW, Bleyer, WA, Zumwalt, RW, Olweny, CL, Kuo, KC, Lakings, DB & Jacobs, SA 1975, Potential biologic markers in Burkitt's lymphoma. in CANCER CHEMOTHER.REP.. 4 edn, vol. 59, pp. 721-727.
Waalkes TP, Gehrke CW, Bleyer WA, Zumwalt RW, Olweny CL, Kuo KC et al. Potential biologic markers in Burkitt's lymphoma. In CANCER CHEMOTHER.REP.. 4 ed. Vol. 59. 1975. p. 721-727
Waalkes, T. P. ; Gehrke, C. W. ; Bleyer, W. A. ; Zumwalt, R. W. ; Olweny, C. L. ; Kuo, K. C. ; Lakings, D. B. ; Jacobs, S. A. / Potential biologic markers in Burkitt's lymphoma. CANCER CHEMOTHER.REP.. Vol. 59 4. ed. 1975. pp. 721-727
@inbook{0e21a3fe4b92456bb7c449a39f61fc36,
title = "Potential biologic markers in Burkitt's lymphoma",
abstract = "Specific biochemical molecules used as potential biologic markers, including modified nucleosides, polyamines, and pyrimidine catabolic end products, were quantitatively measured in the urine of seven patients with Burkitt's lymphoma before, during, and after one or more courses of therapy. The results of this preliminary study demonstrated that patients with this disease frequently excrete significantly increased amounts of modified nucleosides (considered to be derived primarily from transfer ribonucleic acid), polyamines, and β aminoisobutyric acid during the course of their disease. With successful treatment and rapid destruction of tumor cells, a concomitant rise in these molecules occurs. Elevations were observed prior to chemotherapy and changes in levels associated with treatment or tumor progression appeared to correlate with disease status and to aid in assessing antitumor response. Periodic follow up analysis of these molecules may be helpful in appraising relapse or recurrence of the malignancy prior to overt evidence of tumor by existing clinical means.",
author = "Waalkes, {T. P.} and Gehrke, {C. W.} and Bleyer, {W. A.} and Zumwalt, {R. W.} and Olweny, {C. L.} and Kuo, {K. C.} and Lakings, {D. B.} and Jacobs, {S. A.}",
year = "1975",
language = "English (US)",
volume = "59",
pages = "721--727",
booktitle = "CANCER CHEMOTHER.REP.",
edition = "4",

}

TY - CHAP

T1 - Potential biologic markers in Burkitt's lymphoma

AU - Waalkes, T. P.

AU - Gehrke, C. W.

AU - Bleyer, W. A.

AU - Zumwalt, R. W.

AU - Olweny, C. L.

AU - Kuo, K. C.

AU - Lakings, D. B.

AU - Jacobs, S. A.

PY - 1975

Y1 - 1975

N2 - Specific biochemical molecules used as potential biologic markers, including modified nucleosides, polyamines, and pyrimidine catabolic end products, were quantitatively measured in the urine of seven patients with Burkitt's lymphoma before, during, and after one or more courses of therapy. The results of this preliminary study demonstrated that patients with this disease frequently excrete significantly increased amounts of modified nucleosides (considered to be derived primarily from transfer ribonucleic acid), polyamines, and β aminoisobutyric acid during the course of their disease. With successful treatment and rapid destruction of tumor cells, a concomitant rise in these molecules occurs. Elevations were observed prior to chemotherapy and changes in levels associated with treatment or tumor progression appeared to correlate with disease status and to aid in assessing antitumor response. Periodic follow up analysis of these molecules may be helpful in appraising relapse or recurrence of the malignancy prior to overt evidence of tumor by existing clinical means.

AB - Specific biochemical molecules used as potential biologic markers, including modified nucleosides, polyamines, and pyrimidine catabolic end products, were quantitatively measured in the urine of seven patients with Burkitt's lymphoma before, during, and after one or more courses of therapy. The results of this preliminary study demonstrated that patients with this disease frequently excrete significantly increased amounts of modified nucleosides (considered to be derived primarily from transfer ribonucleic acid), polyamines, and β aminoisobutyric acid during the course of their disease. With successful treatment and rapid destruction of tumor cells, a concomitant rise in these molecules occurs. Elevations were observed prior to chemotherapy and changes in levels associated with treatment or tumor progression appeared to correlate with disease status and to aid in assessing antitumor response. Periodic follow up analysis of these molecules may be helpful in appraising relapse or recurrence of the malignancy prior to overt evidence of tumor by existing clinical means.

UR - http://www.scopus.com/inward/record.url?scp=0016838909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016838909&partnerID=8YFLogxK

M3 - Chapter

C2 - 1175166

AN - SCOPUS:0016838909

VL - 59

SP - 721

EP - 727

BT - CANCER CHEMOTHER.REP.

ER -